iCellate Medical initiates a genetic sequencing project to further understand the causes of cancer


Stockholm, Sweden – May 27, 2016 – iCellate Medical has initiated a project in genetic sequencing. By complementing its cutting edge circulating tumor cell (CTC) isolation technology with downstream genetic analyses, iCellate can soon add new information to identify the cellular drivers of the tumor on a cell-by-cell basis. This information is key to ensure that there is in fact a cancer at an early stage when there are still no symptoms, and to guide the new targeted therapies when the cancer diagnosis is established.